Is UNII-VZ8RRZ51VK Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use UNII-VZ8RRZ51VK? Is UNII-VZ8RRZ51VK safe for nursing mother and child? Does UNII-VZ8RRZ51VK extracts into breast milk? Does UNII-VZ8RRZ51VK has any long term or short term side effects on infants? Can UNII-VZ8RRZ51VK influence milk supply or can UNII-VZ8RRZ51VK decrease milk supply in lactating mothers?

Excreted into breast milk in non-significant amount without harm effects observed among breastfed infants of mothers treated with UNII-VZ8RRZ51VK. In addition, a low oral bioavailability renders concentration in the infant's plasma be nil or low. Be aware of false negative results that may be obtained from infants with bacterial cultures when the mother is on antibiotics and higher risk of acute diarrhea by alteration of normal gut flora. When used in eye drops, because of a low dose and topical application with minimal absorption in the serum, it is compatible while breastfeeding.

UNII-VZ8RRZ51VK is poorly excreted into breastmilk. Newborn infants apparently absorb small amounts of other aminoglycosides, but serum levels with typical three times per day dosages are far below those attained when treating newborn infections and systemic effects of UNII-VZ8RRZ51VK are unlikely. Older infants would be expected to absorb even less UNII-VZ8RRZ51VK. Because there is little variability in the milk UNII-VZ8RRZ51VK levels during multiple daily dose regimens, timing breastfeeding with respect to the dose is of little or no benefit in reducing infant exposure. Data are not available with single daily dose regimens. Monitor the infant for possible effects on the gastrointestinal flora, such as diarrhea, candidiasis (e.g., thrush, diaper rash) or rarely, blood in the stool indicating possible antibiotic-associated colitis. Maternal use of an ear drop or eye drop that contains UNII-VZ8RRZ51VK presents little or no risk for the nursing infant [4]

An infant was breastfed (extent not stated) until the 4th month postpartum. At 2 months of age, his mother was given a 2-week course of UNII-VZ8RRZ51VK 150 mg three times daily plus meropenem for a cystic fibrosis exacerbation. infant displayed no change in stool pattern during the maternal treatment and had normal renal function at 6 months of age.[4][5]